PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats

Journal of Psychopharmacology

Volumn 26, Issue 9, 2012, Pages 1265-1270

  McLean, Samantha L ^a   Idris, Nagi F ^a   Grayson, Ben ^a   Gendle, David F ^a   MacKie, Claire ^b   Lesage, Anne S ^b   Pemberton, Darrel J ^b   Neill, Jo C ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

7 nACh receptors; attentional set shifting; cognition; female rat; phencyclidine; schizophrenia

Indexed keywords

BUNGAROTOXIN RECEPTOR; N (5 CHLORO 2,4 DIMETHOXYPHENYL) N' (5 METHYL 3 ISOXAZO LYL)UREA; NICOTINIC AGENT; PHENCYCLIDINE; PNU 120596; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTIONAL SET SHIFTING; COGNITIVE DEFECT; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG MECHANISM; FEMALE; MENTAL PERFORMANCE; MENTAL TASK; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TREATMENT OUTCOME;

ALLOSTERIC REGULATION; ANIMALS; ATTENTION; BEHAVIOR, ANIMAL; BRAIN; COGNITION DISORDERS; DISCRIMINATION LEARNING; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HALLUCINOGENS; ISOXAZOLES; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; NICOTINIC AGONISTS; PHENCYCLIDINE; PHENYLUREA COMPOUNDS; RATS; RATS, INBRED STRAINS; RECEPTORS, NICOTINIC; TISSUE DISTRIBUTION;

EID: 84865025138     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111431747     Document Type: Article

References (38)

1. Berg EA. A simple objective treatment for measuring flexibility in thinking. J Gen Psychol. 1948 ; 39: 15-22
2. Bertrand D, Gopalakrishnan M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol. 2007 ; 74: 1115-1163
3. Birrell JM, Brown VJ. Medial frontal cortex mediates perceptual attentional set-shifting in the rat. J Neurosci. 2000 ; 20: 4320-4324
4. Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology. 2000 ; 23: 351-364
5. Brown DC, Nichols JA, Thomas F, Dinh L, Atzori M. Nicotinic modulation of auditory attentional shift in the rat. Behav Brain Res. 2010 ; 210: 273-279
6. Chan WK, Wong PT-H, Sheu F-S. Frontal cortical α7 and α4Î2 nicotinic acetylcholine receptors in working and reference memory. Neuropharmacology. 2007 ; 52: 1641-1649
7. Egerton A, Ried L, McGregor S, Cochran SM, Morris BJ, Pratt JA. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set-shifting and prepulse inhibition in rats. Psychopharmacology (Berl). 2008 ; 198: 37-49
8. Freedman R, Hall M, Adler LE, Leonard S. Evidence in post-mortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995 ; 38: 22-33
9. Goetghebeur P, Dias R. Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rats-a back translational study. Psychopharmacology (Berl). 2009 ; 202: 287-293
10. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl). 2004 ; 174: 3-16
11. Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull. 2007 ; 33: 1100-1119
12. Harris JG, Kongs S, Allensworth D, Martin L, Tregellas J, Sullivan B, et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology. 2004 ; 29: 1378-1385
13. Haut MW, Cahill J, Cutlip WD, Stevenson JM, Makela EH, Bloomfield SM. On the nature of Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry Res. 1996 ; 65: 15-22
14. Hurst RS, Hajós M, Raggenbass M, Wall TM, Higdon NR, Lawson JA. A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterisation. J Neurosci. 2005 ; 25: 4396-4405
15. Jones CA, Watson DJG, Fone KCF. Animal models of schizophrenia. Br J Pharmacol. 2011 ; 164: 1162-1194
16. Keefe RS, Sweeney JA, Gu H, Hamar RM, Perkins DO, McEnvoy JP, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognition function in early psychosis: a randomised, double-blind 52-week comparison. Am J Psychiatry. 2007 ; 164: 1061-1071
17. Kolb B, Wilshaw IQ. Performance of schizophrenic patients on tests sensitive to left or right frontal temporal, or parietal function in neurological patients. J Nerv Ment Dis. 1983 ; 171: 435-443
18. Krause RM, Buisson B, Bertrand S, Corringer PJ, Galzi JL, Changeux JP, et al. Ivermectin: a positive allosteric effector of the alpha 7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol. 1998 ; 53: 283-294
19. Leiser SC, Bowlby MR, Comery TA, Dunlop J. A cog in cognition: How the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther. 2009 ; 122: 302-311
20. Levin ED, Bushnell PJ, Rezvani AH. Attention-modulating effects of cognitive enhancers. Pharmacol Biochem Behav. 2011 ; 99: 146-154
21. Livingstone PD, Srinivasan J, Kew JNC, Dawson LA, Gotti C, Moretti M, et al. α7 and non-α7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci. 2009 ; 29: 539-550
22. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 ; 11 (Suppl 1). 11-18
23. McLean SL, Beck JP, Woolley ML, Neill JC. A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res. 2008 ; 189: 152-158
24. McLean SL, Grayson B, Idris NF, Lesage AS, Pemberton DJ, Mackie C, et al. Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy for cognitive dysfunction in schizophrenia. Eur Neuropsychopharmacol. 2011 ; 21: 333-343
25. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010 ; 128: 419-432
26. Pantelis C, Barber FZ, Barnes TRE, Nelson HE, Owen AM, Robbins TW. Comparison of set shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res. 1999 ; 37: 251-270
27. Quick MW, Lester RAJ. Desensitisation of neuronal nicotinic receptors. J Neurobiol. 2002 ; 53: 457-478
28. Rodefer JS, Murphy ER, Baxter MG. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci. 2005 ; 21: 1070-1076
29. Rodefer JS, Nguyen TN, Karlsson , Arnt J. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by Sertindole and a 5-HT6 receptor antagonist: Comparison among antipsychotics. Neuropsychopharmacology. 2008 ; 33: 2657-2666
30. Rushforth SL, Allison C, Wonnacott S, Shoaib M. Subtype-selective nicotinic agonists enhance olfactory working memory in normal rats: a novel use of the odour span task. Neurosci Lett. 2010 ; 471: 114-118
31. Saleem MM, Harte MK, Marshall KM, Neill JC. Investigation into cognitive function in first episode psychosis patients. Schizophr Res. 2010 ; 117: 215
32. Schreiber R, Dalmus M, De Vry J. Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology (Berl). 2002 ; 159: 248-257
33. Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology. 2002 ; 27: 479-497
34. Snigdha S, Li Z, Dai J, Shahid M, Neill JC, Meltzer H Washington: Society for Neuroscience ; 2008 2008 :
35. Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S, et al. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther. 2011 ; 336: 242-53
36. White HK, Levin ED. Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology (Berl. 2004 ; 171: 465-71
37. Young GT, Zwart R, Walker AS, Sher E, Millar NS. Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci U S A. 2008 ; 105: 14686-14691
38. Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T. In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology. 2006 ; 51: 1181-1191